Patent details

Basic Information

Publication number:

EP2742149

PCT Application Number:

PCT/EP/2012/003339

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP127439016

PCT Publication Number:

WO/2013/020690

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

PREDICTING RESPONSE TO ANTI-CD20 THERAPY IN DLBCL PATIENTS

French Title of Invention:

PRÉDICTION D'UNE SENSIBILITÉ À UNE THÉRAPIE ANTI-CD20 CHEZ DES PATIENTS ATTEINTS DE DLBCL

German Title of Invention:

VORHERSAGE DES ANSPRECHENS VON DLBCL-PATIENTEN AUF EINE ANTI-CD20-THERAPIE

SPC Number:

Dates

Filing date:

04/08/2012

Grant date:

11/01/2017

EP Publication Date:

11/01/2017

PCT Publication Date:

14/02/2013

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

18/06/2014

EP B1 Publication Date:

11/01/2017

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

04/08/2017

Expiration date:

04/08/2032

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

04/08/2012

 

 

Name:

F. Hoffmann-La Roche AG

Address:

Grenzacherstrasse 124, 4070 Basel, Switzerland (CH)

Name:

Roche Diagnostics GmbH

Address:

Sandhofer Strasse 116, 68305 Mannheim, Germany (DE)

Inventor

1

Name:

LIU Wei-Min

Address:

United States (US)

2

Name:

LIH Chih-Jian

Address:

United States (US)

3

Name:

LI Yan

Address:

United States (US)

4

Name:

TAI Yu Chuan

Address:

United States (US)

Priority

Priority Number:

201113205469

Priority Date:

08/08/2011

Priority Country:

United States (US)

Classification

Main IPC Class:

C12Q 1/68;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages